

## **Department of Planning and Budget 2013 Fiscal Impact Statement**

**1. Bill Number:** HB 1422

<b>House of Origin</b>	<input checked="" type="checkbox"/>	Introduced	<input type="checkbox"/>	Substitute	<input type="checkbox"/>	Engrossed
<b>Second House</b>	<input type="checkbox"/>	In Committee	<input type="checkbox"/>	Substitute	<input type="checkbox"/>	Enrolled

**2. Patron:** O'Bannon, John M. III

**3. Committee:** Health, Welfare and Institutions

**4. Title:** Interchangeable biosimilar biological products; permits pharmacists to dispense

**5. Summary:** The proposed legislation permits pharmacists to dispense a biosimilar that has been licensed by the U.S. Food and Drug Administration as interchangeable with a prescribed biological product unless the prescriber indicates such substitution is not authorized or the patient insists on dispensing of the prescribed biological product. The bill requires any pharmacist who dispenses an interchangeable biosimilar to inform the patient prior to dispensing the biosimilar, provide notification of the substitution to the prescriber, and record the brand name or the product name and name of the manufacturer of the biosimilar on the record of dispensing and the prescription label.

**6. Budget Amendment Necessary:** No

**7. No Fiscal Impact**

**8. Fiscal Implications:** None

**9. Specific Agency or Political Subdivisions Affected:** None

**10. Technical Amendment Necessary:** No

**11. Other Comments:** This bill is a companion to SB 1285.

**Date:** 1/7/13

**Document:** G:\2013 Fiscal Year\2013 GA Session\EFIS\HB1422.docx